Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The current ratio is N/A as of Tuesday, October 6, 2026.
CURRENT RATIO
N/A
Market Cap
$747.61M
Current Ratio
18.86
TTM Avg
23.23
3Y Avg
26.78
5Y Avg
32.61
Market Cap
$753.02M
Current Ratio
9.39
TTM Avg
11.79
3Y Avg
11.79
5Y Avg
11.79
Market Cap
$761.37M
Current Ratio
2.07
TTM Avg
1.18
3Y Avg
1.89
5Y Avg
3.24
Market Cap
$723.18M
Current Ratio
16.09
TTM Avg
8.04
3Y Avg
7.87
5Y Avg
9.13
Market Cap
$721.69M
Current Ratio
0.95
TTM Avg
4.92
3Y Avg
2.98
5Y Avg
5.72
Market Cap
$765.30M
Current Ratio
1.38
TTM Avg
2.71
3Y Avg
3.18
5Y Avg
5.09
Market Cap
$714.37M
Current Ratio
19.31
TTM Avg
14.05
3Y Avg
7.67
5Y Avg
5.91
Market Cap
$709.65M
Current Ratio
1.03
TTM Avg
1.26
3Y Avg
1.17
5Y Avg
1.16
| NAME | MARKET CAP | CURRENT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Apnimed, Inc. (APMD) | $742.70M | N/A | N/A | N/A | N/A |
| Design Therapeutics, Inc. (DSGN)vs › | $747.61M | 18.86 | 23.23 | 26.78 | 32.61 |
| Attovia Therapeutics, Inc. (ATTO)vs › | $753.02M | 9.39 | 11.79 | 11.79 | 11.79 |
| Mesa Laboratories, Inc. (MLAB)vs › | $761.37M | 2.07 | 1.18 | 1.89 | 3.24 |
| Candel Therapeutics, Inc. (CADL)vs › | $723.18M | 16.09 | 8.04 | 7.87 | 9.13 |
| Achieve Life Sciences, Inc. (ACHV)vs › | $721.69M | 0.95 | 4.92 | 2.98 | 5.72 |
| Sana Biotechnology, Inc. (SANA)vs › | $765.30M | 1.38 | 2.71 | 3.18 | 5.09 |
| Avalo Therapeutics, Inc. (AVTX)vs › | $714.37M | 19.31 | 14.05 | 7.67 | 5.91 |
| Collegium Pharmaceutical, Inc. (COLL)vs › | $709.65M | 1.03 | 1.26 | 1.17 | 1.16 |
| Geron Corporation (GERN)vs › | $776.24M | 6.92 | 5.11 | 3.93 | 4.38 |
Current Ratio
N/A
Quick Ratio
N/A
Current Ratio = Current Assets / Current Liabilities
The current ratio measures short-term liquidity — a company's ability to cover current liabilities with current assets. Above 1.0 indicates positive working capital.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
